Metastatic CSCs overexpress EpCAM antigen [69], and the administration of EpCAM-CAR NK-92 cell-coexpressing IL-15 has been shown to induce CAR NK cells proliferation with high selective activity against EpCAM-positive carcinoma cells in vivo [70]. This evidence concerns the gene EPCAM and carcinoma.